TickerGuard
Buy Day today: Good (62) Broad market participation · no major macro event
DERM

Journey Medical Corp

Healthcare · Drug Manufacturers - Specialty & Generic

7.40$ +0.0% vs. previous close Closing price · As of: Sep 17, 2026

Ownership

Ownership Structure

Who owns Journey Medical Corp (DERM)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 70.2% of the shares are freely tradable; institutional investors hold 55.8%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 55.8%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 32.3%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 70.2%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 18.7%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 22Mio.

Largest Shareholders

Institutions

Institutions DERM
Name Stake (%) Shares Change (%) Date
Wasatch Advisors LP 10.13 2,858,930 +34.0 06/30/2026
TANG CAPITAL MANAGEMENT LLC 5.70 1,610,000 -13.2 03/31/2026
Vanguard Capital Management, LLC 3.83 1,082,080 +0.0 03/31/2026
BlackRock Inc 3.45 972,862 +35.2 03/31/2026
Punch & Associates Inv Mgmt Inc 1.90 536,000 +0.0 06/30/2026
Pale Fire Capital SE 1.87 528,584 +9.7 06/30/2026
J. Goldman & Co LP 1.77 500,188 -37.3 03/31/2026

Funds

Funds DERM
Name Stake (%) Shares Change (%) Date
Wasatch Micro Cap 4.91 1,384,940 +69.2 06/30/2026
Wasatch Micro Cap Value Composite 2.89 814,349 +5.2 06/30/2026
Wasatch Micro Cap Value 2.89 814,349 +13.0 06/30/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?